ATAI Investor Presentation Deck
Additionally, a Phase 2 study in DPNP of RL-007 also showed
statistically significant positive cognitive signals
RL-007 low doses enhanced learning and memory
Verbal learning (DPNP)
Placebo
Cohen's d effect size)
Diff. vs.
0.35
0.25
0.2
0.15
0.1
0.05
Pregabalin
(50-100 mg TID)
I
T
RL-007
(40 or 80 mg TID)
Dose
RL-007
(150 or 300 mg TID)
Delayed recall (DPNP)
Cohen's d effect size)
Diff. vs. Placebo
0.4
0.3
0.2
0.1
lo
-0.1
-0.2
-03
Pregabalin
(50-100 mg TID)
(Phase 2 exploratory endpoints - 180 patients)
Indicates direction of improvement
Note: * = P<0.05 vs Placebo; **missed significance (P=0.075); Diabetic Peripheral Neuropathic Pain (DPNP) n=60 patients/treatment group; dosed TID; randomized, cross-over design
1
I
I
RL-007
(40 or 80 mg TID)
Dose
I
I
23
**
RL-007
(150 or 300 mg TID)View entire presentation